We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Medicsight | MDST | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.45 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.45 |
| Top Posts |
|---|
Posted at 18/3/2012 16:38 by gregpants Please share your personal experiences and theories on this whole orchestration to deprive shareholders of their money and for MDT to absorb MDST and all the cash/IP for 50% of its cost. MDST had £3 million in cash which now due to the 'proposal' by 'MDST' which is 52% owned by MDT with the same director, all PI's lose their shares and MDT absorb the entire company. A friend of mine is writing an article that will be released to the national press and which will hopefully destroy the reputation of both MDT and MDST when people across the country see that these guys are nothing short of thieves. We are also looking to take a case to the FSA and to ensure that both MDST and MDT are prevented from trading on the exchanges.Please do add to this thread, personal stories - are you a hard working family man who has had your saving stolen by the wealthy directors of MDT? The article needs this stuff, along with your theories of how this whole thing was orchestrated. |
Posted at 24/8/2011 10:59 by mikeja We should also note that one of the cos businesses is now operated out of the UAE.At the end of 2009 a loan was made to a co called Dunamis run by 2 of the directors operating out of the UAE,after a postponement it was repaid-or so they say= but what the hell was MDST doing lending money to some entity totally unconnected business wise?There is also a shareholder Al Rajhi Holdings which owns almost 6% of the co.This is going to be sucked into the UAE and diluted out of existence unless we keep the quote. |
Posted at 22/8/2011 22:22 by wiganer Lest ye forget:June 20 2007 Dear Shareholder, You may have seen the recent coverage in the UK business press announcing Medicsight PLC's intention to list on AIM on the London stock exchange. It gives both of us great pleasure to announce that the much anticipated flotation on AIM will take place tomorrow on June 21 2007. The details of the listing are as follows: Exchange: AIM London Stock Exchange Ticker: MDST Placing price: £1.10 Placing shares issued: 29,090,909 Ordinary shares in issue on admission: 155,524,904 Gross proceeds of the placing: £32,000,000 Net proceeds of the placing: £30,400,000 Market Capitalisation on placing: £171,077,395 This event represents yet another key milestone in the company's history. The proceeds of this transaction will enable us to continue to realise the vision set out at the company's inception, the funds of which will be used: 1. to further bolster the company's product pipeline via organic growth and acquisition 2. to enable long term clinical and commercial commitments to our existing partners At this point, we would like to extend our thanks to all new and existing shareholders for their ongoing and future support and to the Medicsight team, who through their commitment and drive have made it possible for this to happen. Together, we look forward to watching this exciting story unfold. Kind regards Tim Paterson-Brown David Sumner Chairman Chief Executive Ofiicer |
Posted at 22/8/2011 11:22 by happier THE BIG FELLA.I am still holding my shares here. Just feel too disppointed when looking at the more than 80% loss in my portfolio from MDST. This is my reality, how can you tell that I am ramping it? I would like to see this share price up as much as it can. But can you let it happen now? |
Posted at 12/7/2011 10:52 by cumnor Still some hope. Good to see the Amex announcement. They, unlike their regulatory counterparts in London, treat allegations of fraud seriously and this tends to help concentrate minds somewhat. Us regulatory investigators, if they become involved in allegations about listed cos can be blunt (old network does'nt count for much) and are a good test of friendships and previous loyalties, esp if you have any ambition and you are worried your good name could be remotely sullied by even a hint of wrong-doing by so called friends in the past. As regards MDST investigation on-going and nothing proved as yet of course and only allegations up to now. aimo dyor |
Posted at 11/7/2011 20:22 by rickus MGT Capital Investments, Inc. Establishes Special Committee to Launch InvestigationMedicsight (AMEX:MGT) Today : Monday 11 July 2011 MGT Capital Investments, Inc. ("MGT" or "the Company") (NYSE AMEX: MGT) announced today that its Board of Directors has established a special committee to investigate potential misappropriation and/or misdirection of Company funds. MGT's majority-owned subsidiary, Medicsight PLC (London AIM: MDST), has also launched a similar investigation. While it is too early to determine the outcome of these investigations or the financial impact, if any, to the Company, management believes that no potential wrongdoing occurred post February 7, 2011, when the current MGT board was constituted and the current MGT officers were appointed. In the event the investigation results in any finding of wrongdoing, the Company plans to pursue recovery and/or restitution to the fullest extent provided by law. However, in such an event, there can be no assurance of any recovery, or that any recovery will exceed the costs of collection, the costs of any litigation (including settlements as well as legal fees) relating to this matter, or any other costs associated with this matter, including but not limited to payment of taxes or fines, and the findings of unreported claims on the Company's assets. SUSPENSION OF MEDICSIGHT CEO AND RESIGNATION OF MEDICSIGHT BOARD MEMBER On July 8, 2011, the Board of Directors of Medicsight PLC announced that Allan Rowley, Chief Executive Officer of Medicsight, has been suspended from his Executive responsibilities with immediate effect pending the outcome of the investigations. Robert Ladd, Non-Executive Director of Medicsight and interim CEO of MGT, will assume the role of interim Chief Executive Officer of Medicsight until the investigations are concluded. Medicsight also announced that Steven Harris, a recently appointed non-executive director, has tendered his resignation from the Board of Medicsight effective immediately. TEMPORARY SUSPENSION OF TRADING OF MEDICSIGHT STOCK ON THE AIM EXCHANGE IN LONDON On the advice of its Nominated Advisor, Daniel Stewart & Company, Medicsight has also received a temporary suspension of trading of its ordinary shares on London's AIM Exchange pending clarification of the Company's financial position. AMEX LISTING MGT also reported today that it has been granted a one week extension by the NYSE Amex (the "Exchange") to submit a plan of compliance demonstrating its ability to regain compliance with the Exchange listing standards within an 18 month remediation period. The Company intends to submit such plan by July 15, 2011. As reported on June 14, 2011, MGT announced that on June 8, 2011 it received notice from the NYSE Amex (the "Exchange") that it is not in compliance with following Exchange continued listing standards: Section 1003(a)(i) of the Company Guide, resulting from stockholders' equity on March 31, 2011 of less than $2,000,000 and losses from continuing operations and/or net losses in two of its three most recent fiscal years; Section 1003(a)(ii) of the Company Guide with stockholders' equity of less than $4,000,000 and losses from continuing operations and/or net losses in three of its four most recent fiscal years; and Section 1003(a)(iii) with stockholders' equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years. Mr. Ladd commented, "MGT appreciates the Exchange's accommodation given recent events. Following the improvements in corporate governance implemented earlier this year, MGT has every intention of enhancing financial performance and taking steps to regain compliance with all applicable Exchange listing requirements." AMEX TRADING HALT UNTIL FURTHER NOTICE The Exchange has also initiated a trading halt, to be evaluated on a day-to-day basis, pending resumption of trading of Medicsight shares on the AIM Market of the London Stock Exchange and/or the progress of the investigation. The Company is not able to estimate when or if the trading halt will be lifted. All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of revenue, gross profit, expenses, earnings or losses from operations, synergies or other financial items; any statements of the plans, strategies and objectives of management for future operations, including the rate of market development and acceptance of medical imaging technology; the execution of restructuring plans; any statement concerning developments, performance or industry rankings relating to products or services; any statements regarding future economic conditions or performance; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. The risks, uncertainties and assumptions referred to above include the performance of contracts by suppliers, customers and partners; employee management issues; the difficulty of aligning expense levels with revenue changes; and other risks that are described from time to time in company filings with the Securities and Exchange Commission. Such potential risks and uncertainties also include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission. Contacts: MGT Capital Investments, Inc.Robert Ladd, Interim Chief Executive Officerrladd@mgtci.c Medicsight PLCTroy Robinson, Chief Financial Officer Tel: +44 (0)207 605 7950 Daniel Stewart & CoNoelle Greenaway / Oliver Rigby Tel: +44 (0) 207 776 6550www.danielstewar SOURCE MGT Capital Investments, Inc. |
Posted at 10/7/2011 15:51 by cumnor Lets hope this is all a red herring about control but IF there is anything missing from MDST then that it's only some minor mis-demeanour involving tea money sums or travel expenses etc, the kind of thing companies harass their lowly staff for. A suspension of shares is somewhat serious though.The company, we were told, had over 4ml at last count and with a recent FDA nod should be sufficient to see Mdst through to contracts and deals to enable it flourish. Lets hope any possible concerns alluded to are unfounded and the lot is not gone however and we don't have a worst case theoretical situation like where it's been 'lent' to other companies for whatever possible reason and been syphoned away in some Middle Eastern bank account, or such what which has been the hallmark of several Aim entities in the past? If thorough proper investigation does ultimately show definite 'misappropriation' of big sums belonging to shareholders (not referring to anyone in particular) that Mdst needed to get it's products into hospitals saving patients' lives, and which involved certain sacrifice on the parts of patients allowing themselves to be used in trials, then I'd hope those proved to be responsible do the 'honourable' thing (unlikely) and, amongst other consequences, spare their family(ies) the harassment that inevitably follows frauds of any nature, if indeed that is shown to be the case. imo dyor |
Posted at 10/7/2011 13:08 by shifter2 your on verge fda approval so why have we had so many changes in mdst and mgt boardscould they see someone had hand in the till lets hope it comes good not ideal |
Posted at 09/7/2011 09:00 by cumnor Agree, Red army, about the IP and technology being worth probably more than the present mrkt cap alone, whatever cash is left. TG I hold less than 2% of my portfolio in this but annoying anyhow. Would be surprised if we did'nt get something back as the CAD technology with FDA approval and clinical data is imo worth considerably more than 10ml. A for sale sign might be the very thing that gets the diagnostic imaging companies interested as this tech would imo considerably enhance the saleability of their own diagnostic equipment. I also wonder if there is some stand off between the non-overlapping staff of MGT and MDSt as to how best exploit the technology and proceed. Yesterday btw was i believe the final day for mgt to submit it's plan for retaining listing in NY. ? coincidental. The fact the biggest sh in mdst is also US listed with American shareholders will no doubt concentrate the minds of those in MDST who might be interested in preserving a relationship there. US authorities, unlike our own in London, take a keen interest in matters relating to claims of 'mis-appropriation' of shareholder funds and can in general deal harshly where fraud has been shown to have taken place. As there is an investigation ongoing by both companies (hopefully the US regulators will also take an interest) one has to assume innocence of all parties until or if the outcome shows otherwise. The company is debt free with very valuable tech and hopefully some cash so not sure if it can be written off yet. Anyone know any details to add on anything or anyone in MDST that might be of relevance? dyor imo |
Posted at 08/7/2011 15:32 by topinfo TIDMMDST RNS Number : 0892K Medicsight Plc 08 July 2011 8 July 2011 Medicsight PLC ("Medicsight" or "the Company") Suspension of CEO, Suspension of trading of shares Medicsight PLC (AIM: MDST), The Board announces that it has started an investigation into possible misappropriation and/or misdirection of Company funds and that its majority owner MGT Capital Investments Inc. (MGT) has launched a similar investigation. This investigation will be conducted in line with Company policy. The Board has requested a temporary suspension of trading pending clarification of the Company's financial position. Allan Rowley, Chief Executive Officer of the Company, has been suspended from his Executive responsibilities with immediate effect pending the outcome of the investigation. Robert Ladd, Non-Executive Director of the Company, will assume the role of interim Chief Executive Officer whilst the Company conducts the investigation. The Board also announces that Steve Harris, the recently appointed non-executive director, has resigned. A further announcement will be made as appropriate. - ENDS - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
